Skip to main content

Aspirin for primary prevention: do potential benefits outweigh the risks?

Buy Article:

$51.00 plus tax (Refund Policy)


The role of aspirin for primary prevention in healthy individuals has been the subject of clinical trials for more than a quarter of a century. Because of this evidence, or sometimes despite it, many individuals self‐administer aspirin to prevent cardiovascular events. This article reviews the published work for aspirin in primary prevention of cardiovascular and malignant diseases and considers whether aspirin would be approved by regulatory authorities for this use if it were to be marketed for this indication today.

Document Type: Research Article


Affiliations: Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, Australia

Publication date: 2009-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more